| Literature DB >> 10877522 |
R A Merendino1, A Arena, S Gangemi, A Ruello, E Losi, A Bene, A Valenti, F P D'Ambrosio.
Abstract
Lithium salt compounds are used to limit the degree and duration of neutropenia in patients receiving chemotherapy for cancer. Interleukin-15 (IL-15) is a cytokine which possesses promoting activities on hematopoiesis and is also involved in antitumor response, activating NK, CTL and LAK cells. In this study we analyzed IL-15 production by monocyte cultures treated with lithium chloride (LiCl). Monocytes were obtained from patients affected by non-metastatic and metastatic breast cancer. LiCl treatment induced IL-15 production by monocytes mainly from non-metastatic patients. Combined lipopolysaccharide/LiCl treatment of monocyte cultures up-regulated IL-15 release compared to those treated with LPS alone (p<0.0001). The modulation of LiCl-induced IL-15 could counteract the immunosuppression state of cancer patients, which should be taken into account when developing new immunotherapeutic strategies.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10877522 DOI: 10.1179/joc.2000.12.3.252
Source DB: PubMed Journal: J Chemother ISSN: 1120-009X Impact factor: 1.714